Investigator-Initiated Trials (IIT) in China

Investigator Initiated Trial Service for Cell and Gene Therapy

China CGT IIT Gateway

Strategic Project Introduction & Structuring Partner

Your Bridge to Investigator-Initiated Trials in China

At Cytoart, we specialize in identifying, structuring, and introducing Cell and Gene Therapy (CGT) projects into China’s hospital-based IIT ecosystem.

We do not operate as a traditional CRO.

Instead, we serve as a strategic gateway — connecting international innovators with capable Chinese clinical institutions and helping both sides build a clear, efficient collaboration framework.

Why China for CGT IIT?

China has become a dynamic environment for early CGT validation:

Hospital-based IIT pathways that allow early clinical exploration
Leading academic centers with strong CAR-T and gene editing expertise
Rapid patient enrollment potential in hematologic and solid tumors
Increasing regulatory clarity under the evolving NMPA framework

The opportunity is real — but navigating it requires the right structure.

Our Role

We focus exclusively on CGT.

Cytoart acts as:

• Project evaluator and strategic screener
• Institutional matchmaking partner
• Cross-border communication coordinator
• Collaboration framework designer

We help define:

Sponsor responsibility structure
Data ownership model
Cost-sharing approach
Governance and communication pathways

Execution is carried out by the hospital or designated clinical partners.

What We Enable

Project Identification

We assess early-stage CGT assets for suitability within the China IIT framework.

Institutional Matching

We introduce selected projects to qualified academic hospitals with proven CGT experience.

Collaboration Structuring

We support both parties in defining roles, regulatory pathways, and data governance before formal engagement.

Optional Operational Coordination

If requested, we can introduce experienced local partners for regulatory, monitoring, or project management services.

Cytoart itself does not assume direct clinical execution responsibility.

Our Focus Areas

We concentrate only on CGT — this is our domain.

Why Cytoart

Deep CGT technical background
Extensive network within Chinese CGT hospitals
Cross-border communication fluency
Clear boundary positioning

We structure opportunity.
We align stakeholders.
We reduce uncertainty before commitment.

Explore a China IIT Pathway

If you are evaluating China as a potential early clinical environment for your CGT program, we welcome a structured discussion.